检索结果-南通市图书馆

High insecticide resistance in the major malaria vector Anopheles coluzzii in Chad Republic

Infectious Diseases of Poverty 2019年第6期8卷 39-50页

作者： Sulaiman S.Ibrahim Amen N.Fadel Magellan Tchouakui Ebai Terence murielle j.wondji Micareme Tchoupo Clement Kerah-Hinzoumbe Samuel Wanji Charles S.wondji Vector Biology Department Liverpool School of Tropical Medicine(LSTM)Liverpool L35 QAUK Department of Biochemistry Bayero UniversityKano PMB 3011Nigeria Centre for Research in Infectious Diseases(CRID) LSTM Research UnitP.O.Box 13591YaoundeCameroon Department of Microbiology and Parasitology University of BueaP.O.Box 63BueaCameroon National Malaria Control Program P.O.Box 2030N'djamenaChad

Background:The Sahel region of Chad Republic is a prime candidate for malaria *** facilitate preelimination efforts in this region,two populations o f A nopheles coluzzii from Central Chad Republic were characterized,their insecticide resistance profile and the possible molecular mechanisms driving the resistance in the field ***:Bloodfed female Anopheles gom biae *** indoor,were collected at N'djamena and Massakory,Chad in 2018 and characterized for species composition,and infection rate was determined using the TaqMan *** to various insecticides was assessed using WHO tube *** bioassays were conducted using various long-lasting insecticidal nets(LLINs).Results were analysed using Chi Square *** resistance(kdr)and ace-1 markers were investigated by TaqMan ***:Anopheles coluzzi was the major vector found in N’djamena(100%)and Massakory(〜94%).N〇Plasm odium was found in 147 bloodfed F0 ***(82 from N'djamena and 65 from Massakory).High intensity pyrethroid resistance was observed with mortalities of<2%for permethrin,deltamethrin and etofenprox,and with<50%and<60%dead following exposure to 10x diagnostic doses of deltamethrin and permethrin,*** both sites,<10%mortalities were observed with *** bioassays with piperonylbutoxide significantly recovered pyrethroid susceptibility in Massakory populations,implicating CYP450s(mortality=13.6%for permethrin,X^2=22.8,df=1,P=0.0006;mortality=13.0%for deltamethrin,x2:8.8,df=1,P<0.00031).Cone-bioassays established complete loss of efficacy of the pyrethroid-based LLINs;and a 100%recovery of susceptibility following exposure to the roof of PermaNet®3.0/containing *** populations were susceptible to malathion,but high bendiocarb resistance was observed in Massakory *** absence o f a ce-1 mutation points to the role of metabolic resistance in the bendiocarb *** 1014F and

关键词： Anopheles coluzzii Malaria Sahel Chad Insecticide Resistance Metabolic Kdr

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

An Optimized Protocol for Myxosporidia (Cnidaria: Myxosporea) DNA Extraction for Molecular Studies

引用

Open journal of Animal Sciences 2020年第3期10卷 378-386页

作者： Guy Benoit Lekeufack-Folefack Bienvenu Feudjio-Dongmo Abraham Fomena Billy Tene-Fossog murielle j. wondji Department of Animal Biology and Physiology University of Yaoundé I Yaoundé Cameroon Centre for Research in Infectious Diseases (CRID) Yaoundé Cameroon Department of Vector Biology Liverpool School of Tropical Medicine University of Liverpool Liverpool UK

Myxosporidia constitute a major group of fish parasites which have a significant negative impact on wild and cultured fish. The used of DNA in Myxosporidia studies has progressed rapidly over the last twenty years, especially in their identification and characterization as well as determination of species diversity and investigation of their evolutionary relationships. Extraction and isolation of pure and high quality DNA are essential for any molecular study, but constitute a challenge for many laboratories especially in low and middle income countries. Myxosporidia plasmodia filled with mature myxospores were isolated from different tissues of Labeo batesii Boulenger, 1911. DNA from myxosporidia myxospores were extracted using a Livak optimized DNAs extraction protocol. Four particular phases of the original protocol were optimized. Yield and absorbance ratios of extracted DNA were determined using spectrophotometer. DNA samples were used as template for the amplification of the 18S rDNA region and amplicons resolved on 1.5% agarose gel for determination of fragment sizes and purity evaluation. The concentration of extracted DNA from all Myxosporidia species ranged from 4.6 to 26 ng/μl with purity indices ranging from 1.88 to 2.12. We successfully amplified the 1050 bp DNA fragment as targeted. The intensity, thickness and clarity of the bands were evidences of non-degradation of DNA. The optimized Livak protocol is simple, low-cost and manageable. Regarding the quantity, purity and quality of extracted DNA, the optimized Livak protocol is highly recommended for Myxosporidia studies.

关键词： DNA Extraction Livak Protocol Optimization Myxosporidia Parasites

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis

引用

World journal of Gastroenterology 2017年第2期23卷 336-344页

作者： Amélie Cayzeele-Decherf Fanny Pélerin Sébastien Leuillet Benoit Douillard Béatrice Housez murielle Cazaubiel Gunnard K jacobson Peter jüsten Pierre Desreumaux Lesaffre Human Care Lesaffre Group Biofortis-Mérieux NutriS ciences Lesaffre Yeast Corporation Lesaffre Group CHU Lille Department of GastroenterologyClaude Huriez Hospital Lille University North of France INSERM U995

AIMTo confirm previous conclusions on Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856 for irritable bowel syndrome (IBS) *** individual patient data meta-analysis was performed on two randomized clinical trials studying the effect of S. cerevisiae CNCM I-3856 supplementation on gastrointestinal (GI) symptoms in IBS subjects. A total of 579 IBS subjects were included. Outcomes were the daily Likert scale scores of abdominal pain/discomfort and bloating [area under the curve (AUC) and weekly means], responder status, and bowel movements (stool frequency and consistency). Statistical analyses were conducted in Intent to Treat (ITT) population, IBS-C subjects and IBS-C subjects with an abdominal pain/discomfort score higher than or equal to 2 at baseline (“IBS-C ≥ 2 subpopulation”).RESULTSS. cerevisiae CNCM I-3856 significantly improved abdominal pain/discomfort and bloating during the second month of supplementation [AUC (W5-W8)] with improvement up to the minimal clinically relevant threshold of 10%: a 12.3% reduction of abdominal pain/discomfort in the ITT population compared to the Placebo group (P = 0.0134) has been observed. In the IBS-C ≥ 2 subpopulation, there were a 13.1% reduction of abdominal pain/discomfort and a 14.9% reduction of bloating compared to the Placebo group (P = 0.0194 and P = 0.0145, respectively). GI symptoms significantly decreased during supplementation but no statistical differences were reported between groups at the end of the supplementation period. Responder status was defined as a subject who experienced a decrease of 1 arbitrary unit (a.u.) or 50% of the abdominal discomfort score from baseline for at least 2 wk out of the last 4 wk of the study. A significant difference between groups was reported in the ITT population, when considering the first definition: subjects in the Active group had 1.510 higher odds to be a responder (reduction of 1 a.u. of abdominal pain/discomfort) comp

关键词： Irritable bowel syndrome Saccharomyces cerevisiae Constipation Abdominal pain Probiotics

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

CRISPR/Cas9-Targeted Knockout of Rice Susceptibility Genes OsDjA2 and OsERF104 Reveals Alternative Sources of Resistance to Pyricularia oryzae

引用

Rice science 2022年第6期29卷 535-544,I0023-I0030页

作者： Fabiano T.P.KTÁVORA Anne Cécile MEUNIER Aurore VERNET murielle PORTEFAIX joëlle MILAZZO Henri ADREIT Didier THARREAU Octávio LFRANCO Angela MEHTA Department of Genetics and Biotechnology Federal University of Juiz de ForaJuiz de Fora-MG 36036330Brazil Embrapa Genetic Resources and Biotechnology Brasília-DF 70770-917Brazil Genetic Improvement and Adaptation of Mediterranean and Tropical Plants Agricultural Research Center for International Development(CIRAD)Montpellier 34398 CEDEX 5France CIRAD-INRAe-Agro Institute University of MontpellierMontpellier 34000France Plant Health Institute of Montpellier CIRADMontpellier 34398France University of Montpellier National Institute of Agronomic ResearchResearch Institute for DevelopmentMontpellier SupAgroMontpellier 34398France Department of Genomics Science and Biotechnology Proteomics Analysis CenterCatholic University of BrasíliaBrasília-DF 71966-900Brazil S-Inova Biotech Catholic University of Dom BoscoCampo Grande-MS 79117-900Brazil

Rice genes OsDjA2 and OsERF104,encoding a chaperone protein and an APETELA2/ethylene-responsive factor,respectively,are strongly induced in a compatible interaction with blast fungus,and also have function in plant susceptibility validated through gene ***,we reported the CRISPR/Cas9 knockout of OsDjA2 and OsERF104 genes resulting in considerable improvement of blast resistance.A total of 15 OsDjA2(62.5%)and 17 OsERF104(70.8%)T_(0)transformed lines were identified from 24 regenerated plants for each target and used in downstream *** of homozygous T1 mutant lines revealed not only a significant decrease in the number of blast lesions but also a reduction in the percentage of diseased leaf area,compared with the infected control *** results supported CRISPR/Cas9-mediated target mutation in rice susceptibility genes as a potential and alternative breeding strategy for building resistance to blast disease.

关键词： gene editing plant-pathogen interaction Magnaporthe pathosystem plant immunity blast resistance S-gene rice

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

EGFR Expression Is Unreliable to Decide for Cetuximab Treatment in Patients with Metastatic Colorectal Cancer: Results from “ERBITUX-OUEST”

引用

Open journal of Internal Medicine 2016年第2期6卷 56-67页

作者： jean-Philippe Metges Erick Gamelin Alain Volant Olivier Capitain jean-François Ramée jean-Luc Raoul jean-Yves Douillard Pierre-Luc Etienne Isabelle Cumin Olivier Dupuis Roger Faroux Marie-Aude Coulon Philippe Deguiral Karine Bideau Nacr Eddine Achour Alain Gourlaouen Corinne Alleaume Annie Wdowik Laurent Miglianico Yann Touchefeu Vincent Klein Alain Penchet Ludovic Rosenfeld Daniel Martin Claire Stampfli jean-jacques Auger Alain Bargain murielle Broyer-Petit jérome Chettrit Louis-Rémi De Ybarlucea Serge Eloit Pierre Marie Girardot Nathalie Heresbach Christian Laboisse Eric Lavoine Gilles Lemasson Claire Magois Sophie Michalak Norbert Padilla joseph Politis Frédéric Staroz Bruno Turlin Arnaud Uguen Viorel Vasiliu Véronique Verriele Fanny Marhuenda Delphine Déniel Lagadec Christian Riché Françoise Grudé Observatoire dédié au Cancer des régions Bretagne et Pays de la Loire France Centre Hospitalier Régional Universitaire (CHRU) Brest France Institut de Cancérologie de l’Ouest (ICO) Paul Papin Angers France Centre Catherine de Sienne Nantes France CRLCC Eugène Marquis Rennes France ICO René Gauducheau Nantes France Centre CARIO-HCPA Plérin France Centre Hospitalier Bretagne Sud (CHBS) Lorient France Clinique Victor Hugo Le Mans France Centre Hospitalier Départemental (CHD) La Roche-sur-Yon France CH Le Mans France Clinique Mutualiste de l’Estuaire Saint-Nazaire France CHIC Quimper France Clinique Pasteur Lanroze Brest France CH MORLAIX France CH Saint-Brieuc France CHBA Vannes France CHP Saint-Grégoire France CHU Nantes France Hopital Privé Océane Vannes France Clinique Saint-Michel et Sainte-Anne Quimper France Pole Santé Sarthe et Loire La Flèche France Polyclinique du Maine Laval France Polyclinique Sud Quimper France CH Laval France Polyclinique Cesson Sévigné France Laboratoire d’anatomie et de cytologie pathologiques Cholet France Cabinet d’anatomie et de cytologie pathologiques Saint-Malo France Laboratoire d’anatomie et de cytologie pathologiques Lorient France Institut d’histopathologie Nantes France Laboratoire de Pathologie Médicale Laval France ARMOR Pathologie Plérin France Laboratoire d’anatomie et de cytologie pathologiques Rennes France Laboratoire d’anatomie et de cytologie pathologiques Angers France Laboratoire Analyses Biologie Glasgow Brest France CHU Angers France Centre d’anatomie et de cytologie pathologiques Le Mans France Cabinet d’anatomie et de cytologie pathologiques Vannes France Laboratoire d’anatomie et de cytologie pathologiques Quimper France CHU Rennes France

Purpose: Although controversial, assessment of epidermal growth factor receptor (EGFR) expression is required for the approved indications of Cetuximab in metastatic colorectal cancer (mCRC). With the objective of improving patient selection, “ERBITUX-OUEST” study aimed at analyzing EGFR status in a large cohort of mCRC patients who received cetuximab without preliminary EGFR screening, and assessing the correlation between EGFR status and response to treatment retrospectively. Patients and methods: 332 patients treated with Irinotecan Cetuximab based regimen after progression on irinotecan or oxaliplatin therapy were included. EGFR status was assessed using three available immunohistochemistry (IHC) tests and in situ hybridization in case of negativity. Clinical outcomes of EGFR-positive and EGFR-non-detected (or considered as negative with at least one test) patients were compared. Results: Of the 332 samples centrally screened, 194 were classified as full-positive (i.e., EGFR-positive for all three tests), 86 as full-negative, and 52 as discordant. One third of the 131 negative samples with FDA approved test should be reclassified as positive with at least one of the two others tests. Regarding results from FDA approved test only, neither objective response rate (ORR), progression-free survival (PFS) nor overall survival (OS) differed significantly between EGFR-negative and EGFR-positive patients (P = 0.788, 0.326 and 0.888, respectively). Similarly, comparison of full-negative to other groups did not show any significant difference in terms of ORR (P = 0.507), PFS (P = 0.222) or OS (P = 0.686). Conclusion: These data strongly argue against mCRC patients selection for Cetuximab treatment based on EGFR expression as measured by currently available IHC technics.

关键词： Metastatic Colorectal Cancer Cetuximab EGFR Expression

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：